ID   FM9
AC   CVCL_C582
SY   FM-9
DR   cancercelllines; CVCL_C582
DR   Cosmic; 808557
DR   Cosmic; 874475
DR   Cosmic; 1047682
DR   Cosmic; 2163781
DR   ECACC; 13012416
DR   ESTDAB; ESTDAB-030
DR   GEO; GSM156036
DR   IARC_TP53; 26108
DR   Progenetix; CVCL_C582
DR   Wikidata; Q54835072
RX   PubMed=7656272;
RX   PubMed=8968104;
RX   PubMed=9288767;
RX   PubMed=9688544;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*01,03; B*08,35; C*04 (PubMed=7656272).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Asp32Gly (c.95A>G); ClinVar=VCV000017578; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000007827; Zygosity=Unspecified (PubMed=17260012).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): ECACC=13012416; ESTDAB=ESTDAB-030
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 11,12
ST   D16S539: 8,11
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 11
ST   FGA: 22
ST   TH01: 8
ST   TPOX: 8,10
ST   vWA: 15,19
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 24
//
RX   PubMed=7656272; DOI=10.1007/BF01527402; PMCID=PMC11037630;
RA   Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P.,
RA   Zeuthen J.;
RT   "Generation of human-melanoma-specific T lymphocyte clones defining
RT   novel cytolytic targets with panels of newly established melanoma cell
RT   lines.";
RL   Cancer Immunol. Immunother. 41:71-81(1995).
//
RX   PubMed=8968104;
RA   Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F.,
RA   Zeuthen J., Bartek J.;
RT   "The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently
RT   altered in melanoma pathogenesis.";
RL   Cancer Res. 56:5475-5483(1996).
//
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
//
RX   PubMed=9688544; DOI=10.1016/S0014-5793(98)00603-6;
RA   Dzhandzhugazyan K.N., Kirkin A.F., thor Straten P., Zeuthen J.;
RT   "Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated
RT   human melanomas.";
RL   FEBS Lett. 430:227-230(1998).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//